Niagen Bioscience Inc (NAGE)

$5.01 +0.15 (3.09%)
Market Cap 387.86M
Revenue (ttm) 99.60M
Net Income (ttm) 8.55M
EPS (ttm) N/A
PE Ratio 30.88
Forward PE 16.84
Profit Margin 8.58%
Debt to Equity Ratio 0.00
Volume 1,018,900
Avg Vol 837,594
Day's Range N/A - N/A
Shares Out 79.81M
Stochastic %K 47%
Beta 2.35
Analysts Strong Sell
Price Target $15.25

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 388 6706
Address:
10900 Wilshire Blvd, Suite 600, Los Angeles, United States
wycliff
wycliff Feb. 23 at 8:21 PM
$NAGE https://x.com/niagenbio/status/2026016772470517935?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
wycliff
wycliff Feb. 23 at 8:14 PM
$NAGE https://www.linkedin.com/posts/niagen-nr-nicotinamideriboside-share-7431782443583696896-RPnS?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
water_raccoon
water_raccoon Feb. 23 at 7:10 PM
$NAGE https://eventsignup.ku.dk/nadforhealth/programme "NAD Augmentation Therapy as a Disease-Modifying Approach for Neurodegeneration" 09:45-10:15 Speaker: Charalampos Tzoulis - University of Bergen & Haukeland University Hospital
1 · Reply
MattManzanita
MattManzanita Feb. 22 at 6:50 PM
$NAGE -Nothing new, but a concise sumamry regarding NAD. https://link.springer.com/chapter/10.1007/978-3-032-11608-6_5
0 · Reply
MattManzanita
MattManzanita Feb. 22 at 4:47 AM
$NAGE In a search on YouTube to determine if Avid Trader has posted a new video, the one linked popped up, which was made 6 days ago. It sounds like an AI conversation, but I think it is largely valid in its assessments. AI, or however it was made, is inaccurate in indicating that the Q4 results would be made available in May, rather than March. NoPark, etc, are not specifically mentioned. https://www.youtube.com/watch?v=J8pkUdaLic8&t=33s
0 · Reply
Proteus92
Proteus92 Feb. 21 at 4:47 PM
$NAGE This thing is just sitting on the water.... I do wonder if this can ever get itself up again, or is it finished as far as double digits go?
1 · Reply
DanielStricklin1098
DanielStricklin1098 Feb. 21 at 4:50 AM
$NAGE National Atlantic Group microcap with limited disclosure. Trading dynamics dominate valuation. Liquidity risk is high.
0 · Reply
MattManzanita
MattManzanita Feb. 21 at 2:11 AM
$NAGE What might Niagen Bio be doing with its NRH and NMMH patents? https://faseb.onlinelibrary.wiley.com/doi/pdfdirect/10.1096/fj.202501925R
1 · Reply
wycliff
wycliff Feb. 20 at 6:53 PM
$NAGE https://www.linkedin.com/posts/moments-from-an-incredible-weekend-with-caa-ugcPost-7430661849391730690-BYs1?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Feb. 20 at 4:02 PM
$NAGE https://www.reddit.com/r/NicotinamideRiboside/s/iZCBbqquh6
0 · Reply
Latest News on NAGE
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Feb 9, 2026, 8:34 AM EST - 14 days ago

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

Feb 6, 2026, 8:32 AM EST - 17 days ago

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

Jan 15, 2026, 8:34 AM EST - 5 weeks ago

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast

Dec 22, 2025, 8:32 AM EST - 2 months ago

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Nov 15, 2025, 5:41 AM EST - 3 months ago

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Nov 13, 2025, 8:32 AM EST - 3 months ago

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Nov 12, 2025, 7:52 PM EST - 3 months ago

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Niagen Bioscience Announces $10 Million Share Repurchase Program

Nov 6, 2025, 8:07 AM EST - 3 months ago

Niagen Bioscience Announces $10 Million Share Repurchase Program

Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 6:56 PM EST - 3 months ago

Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Nov 4, 2025, 4:02 PM EST - 3 months ago

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 21, 2025, 8:32 AM EDT - 4 months ago

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

Oct 6, 2025, 8:32 AM EDT - 5 months ago

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

Oct 1, 2025, 8:32 AM EDT - 5 months ago

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Sep 16, 2025, 8:32 AM EDT - 5 months ago

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Aug 6, 2025, 4:02 PM EDT - 7 months ago

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:32 AM EDT - 7 months ago

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 23, 2025, 8:34 AM EDT - 7 months ago

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Jul 14, 2025, 8:32 AM EDT - 8 months ago

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Jul 8, 2025, 8:32 AM EDT - 8 months ago

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

Jun 24, 2025, 4:27 PM EDT - 8 months ago

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Jun 20, 2025, 8:32 AM EDT - 8 months ago

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Niagen Bioscience to Participate in the BIO 2025 International Convention

Jun 11, 2025, 8:31 AM EDT - 9 months ago

Niagen Bioscience to Participate in the BIO 2025 International Convention

Niagen Bioscience: High Conviction, High Expectations

Jun 11, 2025, 6:48 AM EDT - 9 months ago

Niagen Bioscience: High Conviction, High Expectations

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Jun 9, 2025, 8:32 AM EDT - 9 months ago

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Jun 4, 2025, 8:32 AM EDT - 9 months ago

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

May 10, 2025, 1:40 PM EDT - 10 months ago

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 7, 2025, 4:02 PM EDT - 10 months ago

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

May 5, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Apr 29, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 28, 2025, 8:34 AM EDT - 10 months ago

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Apr 7, 2025, 10:32 PM EDT - 11 months ago

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Apr 7, 2025, 8:32 AM EDT - 11 months ago

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

Mar 20, 2025, 8:34 AM EDT - 1 year ago

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

Mar 19, 2025, 8:34 AM EDT - 1 year ago

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

Mar 13, 2025, 8:34 AM EDT - 1 year ago

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 1 year ago

ChromaDex to Present at the 37th Annual Roth Conference

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

Mar 6, 2025, 10:30 AM EST - 1 year ago

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 8:53 PM EST - 1 year ago

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

Mar 4, 2025, 4:02 PM EST - 1 year ago

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 25, 2025, 4:07 PM EST - 1 year ago

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 6, 2025, 8:32 AM EST - 1 year ago

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

Dec 3, 2024, 8:34 AM EST - 1 year ago

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

Nov 14, 2024, 8:32 AM EST - 1 year ago

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

Nov 7, 2024, 8:32 AM EST - 1 year ago

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript

Nov 1, 2024, 2:48 PM EDT - 1 year ago

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 4:04 PM EDT - 1 year ago

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Oct 28, 2024, 8:32 AM EDT - 1 year ago

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Oct 23, 2024, 8:34 AM EDT - 1 year ago

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

Oct 15, 2024, 8:32 AM EDT - 1 year ago

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

Sep 26, 2024, 4:12 PM EDT - 1 year ago

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

wycliff
wycliff Feb. 23 at 8:21 PM
$NAGE https://x.com/niagenbio/status/2026016772470517935?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
wycliff
wycliff Feb. 23 at 8:14 PM
$NAGE https://www.linkedin.com/posts/niagen-nr-nicotinamideriboside-share-7431782443583696896-RPnS?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
water_raccoon
water_raccoon Feb. 23 at 7:10 PM
$NAGE https://eventsignup.ku.dk/nadforhealth/programme "NAD Augmentation Therapy as a Disease-Modifying Approach for Neurodegeneration" 09:45-10:15 Speaker: Charalampos Tzoulis - University of Bergen & Haukeland University Hospital
1 · Reply
MattManzanita
MattManzanita Feb. 22 at 6:50 PM
$NAGE -Nothing new, but a concise sumamry regarding NAD. https://link.springer.com/chapter/10.1007/978-3-032-11608-6_5
0 · Reply
MattManzanita
MattManzanita Feb. 22 at 4:47 AM
$NAGE In a search on YouTube to determine if Avid Trader has posted a new video, the one linked popped up, which was made 6 days ago. It sounds like an AI conversation, but I think it is largely valid in its assessments. AI, or however it was made, is inaccurate in indicating that the Q4 results would be made available in May, rather than March. NoPark, etc, are not specifically mentioned. https://www.youtube.com/watch?v=J8pkUdaLic8&t=33s
0 · Reply
Proteus92
Proteus92 Feb. 21 at 4:47 PM
$NAGE This thing is just sitting on the water.... I do wonder if this can ever get itself up again, or is it finished as far as double digits go?
1 · Reply
DanielStricklin1098
DanielStricklin1098 Feb. 21 at 4:50 AM
$NAGE National Atlantic Group microcap with limited disclosure. Trading dynamics dominate valuation. Liquidity risk is high.
0 · Reply
MattManzanita
MattManzanita Feb. 21 at 2:11 AM
$NAGE What might Niagen Bio be doing with its NRH and NMMH patents? https://faseb.onlinelibrary.wiley.com/doi/pdfdirect/10.1096/fj.202501925R
1 · Reply
wycliff
wycliff Feb. 20 at 6:53 PM
$NAGE https://www.linkedin.com/posts/moments-from-an-incredible-weekend-with-caa-ugcPost-7430661849391730690-BYs1?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Feb. 20 at 4:02 PM
$NAGE https://www.reddit.com/r/NicotinamideRiboside/s/iZCBbqquh6
0 · Reply
okeydokey_artichokey
okeydokey_artichokey Feb. 20 at 3:46 PM
$NAGE Just a preclinical paper, nevertheless nice neuro bioactivity. https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awaf261/8473458?login=false
0 · Reply
wycliff
wycliff Feb. 20 at 2:58 AM
$NAGE https://www.instagram.com/p/DUt7EQijNZl/?igsh=MTBram9qbGdhOWF5MA==
0 · Reply
wycliff
wycliff Feb. 20 at 1:43 AM
$NAGE https://www.marketbeat.com/instant-alerts/brokers-issue-forecasts-for-nage-q4-earnings-2026-02-19/
0 · Reply
wycliff
wycliff Feb. 19 at 11:37 PM
$NAGE https://x.com/optispan_inc/status/2024607203743650186?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
wycliff
wycliff Feb. 19 at 9:39 PM
$NAGE https://events.q4inc.com/attendee/408160538
0 · Reply
BDipNRip
BDipNRip Feb. 19 at 9:25 PM
$NAGE who’s is loading the boat for earning?
2 · Reply
wycliff
wycliff Feb. 19 at 6:14 PM
$NAGE https://raisingnad.com/reddit-ama-with-dr-brenner-we-will-be-able-to-demonstrate-skin-efficacy-with-oral-topical-nr/
0 · Reply
wycliff
wycliff Feb. 19 at 6:06 PM
$NAGE https://raisingnad.com/reddit-ama-with-dr-brenner-ivf-docs-recommend-nr/
0 · Reply
wycliff
wycliff Feb. 19 at 5:31 PM
$NAGE https://finance.yahoo.com/news/spotlight-silence-therapeutics-2-other-120506610.html
0 · Reply
wycliff
wycliff Feb. 19 at 4:46 PM
$NAGE https://x.com/thefanggroupuio/status/2024477402282205615?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
wycliff
wycliff Feb. 18 at 5:58 PM
$NAGE https://x.com/charlesmbrenner/status/2024156827097637024?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
Jimgym
Jimgym Feb. 18 at 4:22 PM
$NAGE https://x.com/charlesmbrenner/status/2024156827097637024?s=46&t=Ult8Uv_K130ADTnsJdWTig
2 · Reply